BioSpace News Archive

SFA Therapeutics, Inc. today announced the appointment of Stefan C. Weiss , MD, MBA, as Chief Medical Officer.

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets.

Cytovale® announced the publication of a new peer reviewed-study in “Academic Emergency Medicine’’ that demonstrates strong diagnostic performance of the company’s IntelliSep® host response test for sepsis detection.

World-renowned physicians and researchers from City of Hope will present new findings and offer expert perspectives on leading-edge cancer research and treatment development at the ASCO Annual Meeting 2024, which will take place in Chicago from May 31.

Humonix Biosciences, Inc. (“Humonix”), a specialty pharmaceutical research company focused on 3D human tissue models capable of mimicking disease states for pharmaceutical and biotechnology clients, today announced the appointment of Dr. Karen Torrejon as the new Chief Executive Officer.

CSL Seqirus, a business of CSL (ASX: CSL), today announced a real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID), showing that a cell-based quadrivalent influenza vaccine (QIVc) prevented more test-confirmed influenza cases among individuals 4–64 years of age compared with the egg-based quadrivalent influenza vaccine (QIVe) over three consecutive U.S. influenza seasons (2017–2020).

Innosphere Engineering Ltd is pleased to announce the launch of recruitment for a randomized, sham-controlled, double-blind clinical trial examining the safety and effectiveness of Novostim 2 transcranial Random Noise Stimulation on ADHD symptoms in pediatric patients.

Gyros Protein Technologies AB announced the introduction of Gyrolab® Generic Rodent Anti-Drug Antibody Kit Reagents for the detection of circulating immune complexes of human IgG with rodent anti-human IgG.

Anaut Inc., a pioneering developer in surgical support software led by CEO Dr. Nao Kobayashi, announced regulatory approval of its groundbreaking medical device, “Eureka α”.

Crossject announces it has extended the geographic coverage of its 22nd December 2023 commercialization agreement with an undisclosed partner for its innovative rescue therapy for epileptic seizures ZEPIZURE®, previously known as ZENEO® Midazolam.